Immune Cell Engagers ICEs Market Size, Share and Growth Analysis 2026 to 2035
Market Segmentation:
Immune Cell Engagers (ICEs) Market by Product Type -
- Bispecific Antibodies
-
- T-cell Engagers (BiTEs, DARTs)
- NK-cell Engagers
- Myeloid Engagers
- Trispecific/Multispecific Antibodies
- Engineered Cell Therapies
-
- TAC-T cells
- CAR-NK with engager payloads
-Market-seg.webp "Immune Cell Engagers (ICEs) Market seg")
Immune Cell Engagers (ICEs) Market by Target Antigen-
- Oncology Targets
-
- Hematologic
- Solid Tumors
- Autoimmune/Inflammatory Targets
-
- B-cell Depletion
- Cytokine Modulation
- Immune Checkpoints
Immune Cell Engagers (ICEs) Market by Mechanism of Action -
- Immune Cell Recruitment
-
- T-cell
- NK-cell
- Macrophage
- Signal Modulation
-
- Co-stimulation
- Cytokine armoring
- Conditional Activation
-
- Protease-cleavable masks
- Tumor microenvironment sensors
Immune Cell Engagers (ICEs) Market by Therapeutic Area-
- Oncology
-
- Hematologic Malignancies:
-
-
- B-cell ALL, NHL (DLBCL, FL)
- Multiple myeloma (BCMA-targeted)
-
-
- Solid Tumors:
-
-
- Breast (HER2)
- Prostate (PSMA)
- Lung (EGFR)
-
- Autoimmune/Inflammatory
-
- Rheumatoid Arthritis
- Lupus
- IBD
Immune Cell Engagers (ICEs) Market by Development Stage -
- Clinical Phase
- Marketed/Approved
By Region-
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Immune Cell Engagers (ICEs) Market Snapshot
Chapter 4. Global Immune Cell Engagers (ICEs) Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2035
4.8. Global Immune Cell Engagers (ICEs) Market Penetration & Growth Prospect Mapping (US$ Mn), 2026-2035
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2026)
4.10. Use/impact of AI on IMMUNE CELL ENGAGERS (ICES) Industry Trends
Chapter 5. Immune Cell Engagers (ICEs) Market Segmentation 1: By Product Type, Estimates & Trend Analysis
5.1. Market Share By Product Type, 2025 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Product Type:
5.2.1. Bispecific Antibodies
5.2.1.1. T-cell Engagers (BiTEs, DARTs)
5.2.1.2. NK-cell Engagers
5.2.1.3. Myeloid Engagers
5.2.2. Trispecific/Multispecific Antibodies
5.2.3. Engineered Cell Therapies
5.2.3.1. TAC-T cells
5.2.3.2. CAR-NK with engager payloads
Chapter 6. Immune Cell Engagers (ICEs) Market Segmentation 2: By Target Antigen, Estimates & Trend Analysis
6.1. Market Share By Target Antigen, 2025 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Target Antigen:
6.2.1. Oncology Targets
6.2.1.1. Hematologic
6.2.1.2. Solid Tumors
6.2.2. 2.2 Autoimmune/Inflammatory Targets
6.2.2.1. B-cell Depletion
6.2.2.2. Cytokine Modulation
6.2.2.3. Immune Checkpoints
Chapter 7. Immune Cell Engagers (ICEs) Market Segmentation 3: By Mechanism of Action, Estimates & Trend Analysis
7.1. Market Share By Mechanism of Action, 2025 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Mechanism of Action:
7.2.1. Immune Cell Recruitment
7.2.1.1. T-cell
7.2.1.2. NK-cell
7.2.1.3. Macrophage
7.2.2. Signal Modulation
7.2.2.1. Co-stimulation
7.2.2.2. Cytokine armoring
7.2.3. Conditional Activation
7.2.3.1. Protease-cleavable masks
7.2.3.2. Tumor microenvironment sensors
Chapter 8. Immune Cell Engagers (ICEs) Market Segmentation 4: By Therapeutic Area, Estimates & Trend Analysis
8.1. Market Share By Therapeutic Area, 2025 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Therapeutic Area:
8.2.1. Oncology
8.2.1.1. Hematologic Malignancies:
8.2.1.1.1. B-cell ALL, NHL (DLBCL, FL)
8.2.1.1.2. Multiple myeloma (BCMA-targeted)
8.2.1.2. Solid Tumors:
8.2.1.2.1. Breast (HER2)
8.2.1.2.2. Prostate (PSMA)
8.2.1.2.3. Lung (EGFR)
8.2.2. Autoimmune/Inflammatory
8.2.2.1. Rheumatoid Arthritis
8.2.2.2. Lupus
8.2.2.3. IBD
Chapter 9. Immune Cell Engagers (ICEs) Market Segmentation 5: By Development Stage, Estimates & Trend Analysis
9.1. Market Share By Development Stage, 2025 & 2035
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Development Stage:
9.2.1. Clinical Phase
9.2.2. Marketed/Approved
Chapter 10. Immune Cell Engagers (ICEs) Market Segmentation 5: Regional Estimates & Trend Analysis
10.1. Global Immune Cell Engagers (ICEs) Market, Regional Snapshot 2025 & 2035
10.2. North America
10.2.1. North America Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2022-2035
10.2.3. North America Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Mechanism of Action, 2022-2035
10.2.4. North America Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Target Antigen, 2022-2035
10.2.5. North America Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Area, 2022-2035
10.2.6. North America Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Development Stage, 2022-2035
10.3. Europe
10.3.1. Europe Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2022-2035
10.3.3. Europe Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Mechanism of Action, 2022-2035
10.3.4. Europe Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Target Antigen, 2022-2035
10.3.5. Europe Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Area, 2022-2035
10.3.6. Europe Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Development Stage, 2022-2035
10.4. Asia Pacific
10.4.1. Asia Pacific Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2022-2035
10.4.3. Asia Pacific Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Mechanism of Action, 2022-2035
10.4.4. Asia Pacific Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Target Antigen, 2022-2035
10.4.5. Asia Pacific Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Area, 2022-2035
10.4.6. Asia Pacific Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Development Stage, 2022-2035
10.5. Latin America
10.5.1. Latin America Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2022-2035
10.5.3. Latin America Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Mechanism of Action, 2022-2035
10.5.4. Latin America Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Target Antigen, 2022-2035
10.5.5. Latin America Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Area, 2022-2035
10.5.6. Latin America Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Development Stage, 2022-2035
10.6. Middle East & Africa
10.6.1. Middle East & Africa Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2035
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2022-2035
10.6.3. Middle East & Africa Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Mechanism of Action, 2022-2035
10.6.4. Middle East & Africa Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Target Antigen, 2022-2035
10.6.5. Middle East & Africa Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Area, 2022-2035
10.6.6. Middle East & Africa Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Development Stage, 2022-2035
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Amgen (Blinatumomab)
11.2.1.1. Business Overview
11.2.1.2. Key Product/Service
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Johnson & Johnson/Genmab (Teclistamab)
11.2.3. Regeneron (Odronextamab)
11.2.4. Pfizer (Elranatamab)
11.2.5. Sanofi (SAR446309)
11.2.6. Affimed (AFM13)
11.2.7. Innate Pharma (IPH6101)
11.2.8. Dragonfly Therapeutics (DF1001)
11.2.9. GT Biopharma (GTB-3550)
11.2.10. Immunocore (Tebentafusp)
11.2.11. Merus (MCLA-158)
11.2.12. Xencor (Plamotamab)
11.2.13. Harpoon Therapeutics (HPN328)
11.2.14. Gilead/Tizona (TTX-080)
11.2.15. Jounce Therapeutics (JTX-8064)
11.2.16. UCB Pharma (CD19×CD3)
11.2.17. Horizon Therapeutics/Amgen (B-cell depleters)
11.2.18. Viela Bio (CD40L×CD3)
11.2.19. MorphoSys (CD19×CD3)
11.2.20. CytomX (Probody TCE)
11.2.21. Xilio Therapeutics (Tumor-activated)
11.2.22. Numab Therapeutics (NM21-1480)
11.2.23. Immatics (IMA401)
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Immune Cell Engagers (ICEs) Market is expected to grow with at a 26.4% CAGR during the forecast period for 2026 to 2035.
Amgen (Blinatumomab), Johnson & Johnson/Genmab (Teclistamab), Regeneron (Odronextamab), Pfizer (Elranatamab), Sanofi (SAR446309), Affimed (AFM13), Innate Pharma (IPH6101), Dragonfly Therapeutics (DF1001), GT Biopharma (GTB-3550), Immunocore (Tebentafusp), Merus (MCLA-158), Xencor (Plamotamab), Harpoon Therapeutics (HPN328), Gilead/Tizona (TTX-080), Jounce Therapeutics (JTX-8064), UCB Pharma (CD19×CD3), Horizon Therapeutics/Amgen (B-cell depleters), Viela Bio (CD40L×CD3), MorphoSys (CD19×CD3), CytomX (Probody TCE), Xilio Therapeutics (Tumor-activated), Numab Therapeutics (NM21-1480), Immatics (IMA401)
Product Type, Target Antigen, Mechanism of Action, Therapeutic Area, Development Stage are the key segments of the Immune Cell Engagers (ICEs) Market.
North America region is leading the Immune Cell Engagers (ICEs) Market.